Plasma Levels of K18 Fragments Do Not Correlate with Alcoholic Liver Fibrosis.
Aged
Alanine Transaminase
/ blood
Analysis of Variance
Aspartate Aminotransferases
/ blood
Biomarkers
/ blood
Chi-Square Distribution
Female
Humans
Keratin-18
/ blood
Liver Cirrhosis
/ etiology
Liver Diseases, Alcoholic
/ blood
Liver Function Tests
/ methods
Male
Middle Aged
Peptide Fragments
/ blood
Predictive Value of Tests
Prognosis
Sensitivity and Specificity
Severity of Illness Index
Statistics, Nonparametric
Apoptosis
Caspases
Fibrosis progression
Noninvasive diagnosis
Journal
Gut and liver
ISSN: 2005-1212
Titre abrégé: Gut Liver
Pays: Korea (South)
ID NLM: 101316452
Informations de publication
Date de publication:
15 01 2019
15 01 2019
Historique:
received:
18
01
2018
revised:
07
04
2018
accepted:
09
04
2018
pubmed:
7
7
2018
medline:
16
5
2019
entrez:
7
7
2018
Statut:
ppublish
Résumé
Noninvasive markers of liver fibrosis in alcoholic liver disease (ALD) are crucial to establish early intervention. Previous studies have suggested that plasma levels of cleaved keratin-18 (K18; M30) fragments can predict the severity of liver disease. The aim of this study was to correlate plasma M30 levels with stages of liver fibrosis in ALD. Patients with ALD (n=139, 79.1% males) and liver histology were included, and plasma samples were collected to quantify plasma M30 levels. Patients were stratified into five groups by fibrosis stage (F0=14; F1=15; F2=35; F3=17; and F4=58) according to the Kleiner score. Differences between groups were evaluated using the chi-square test or analysis of variance. Trends by fibrosis stage were calculated by logistic regression analysis, and sensitivity, specificity and positive and negative predictive values were determined. There were no significant differences in M30 levels among fibrosis stages. The correlation between plasma M30 levels and fibrosis was poor (Pearson's correlation coefficient= 0.13, Spearman rho=0.20 [p=0.02]), and M30 levels did not correlate with alcohol-specific histological features. However, significant correlations of M30 levels with aspartate aminotransferase (Spearman rho=0.653, p<0.001) and alanine aminotransferase (spearman rho=0.432, p<0.001) were found. m30 levels of>200 U/L reveal a sensitivity for predicting cirrhosis of 84.5% with a negative predictive value of 73.5%. Plasma M30 levels are often elevated in ALD and correlate with serum transaminases but do not reflect fibrosis. The usefulness as a prognostic marker awaits evaluation in prospective studies.
Sections du résumé
Background/Aims
Noninvasive markers of liver fibrosis in alcoholic liver disease (ALD) are crucial to establish early intervention. Previous studies have suggested that plasma levels of cleaved keratin-18 (K18; M30) fragments can predict the severity of liver disease. The aim of this study was to correlate plasma M30 levels with stages of liver fibrosis in ALD.
Methods
Patients with ALD (n=139, 79.1% males) and liver histology were included, and plasma samples were collected to quantify plasma M30 levels. Patients were stratified into five groups by fibrosis stage (F0=14; F1=15; F2=35; F3=17; and F4=58) according to the Kleiner score. Differences between groups were evaluated using the chi-square test or analysis of variance. Trends by fibrosis stage were calculated by logistic regression analysis, and sensitivity, specificity and positive and negative predictive values were determined.
Results
There were no significant differences in M30 levels among fibrosis stages. The correlation between plasma M30 levels and fibrosis was poor (Pearson's correlation coefficient= 0.13, Spearman rho=0.20 [p=0.02]), and M30 levels did not correlate with alcohol-specific histological features. However, significant correlations of M30 levels with aspartate aminotransferase (Spearman rho=0.653, p<0.001) and alanine aminotransferase (spearman rho=0.432, p<0.001) were found. m30 levels of>200 U/L reveal a sensitivity for predicting cirrhosis of 84.5% with a negative predictive value of 73.5%.
Conclusions
Plasma M30 levels are often elevated in ALD and correlate with serum transaminases but do not reflect fibrosis. The usefulness as a prognostic marker awaits evaluation in prospective studies.
Identifiants
pubmed: 29976035
pii: gnl18037
doi: 10.5009/gnl18037
pmc: PMC6346996
doi:
Substances chimiques
Biomarkers
0
Keratin-18
0
M30 cytokeratin-18 peptide, human
0
Peptide Fragments
0
Aspartate Aminotransferases
EC 2.6.1.1
Alanine Transaminase
EC 2.6.1.2
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-82Références
Hepatology. 2000 Sep;32(3):477-81
pubmed: 10960438
Clin Chim Acta. 1957 Feb;2(1):70-4
pubmed: 13447217
Hepatology. 2003 Dec;38(6):1449-57
pubmed: 14647056
Cancer Res. 2004 Mar 1;64(5):1751-6
pubmed: 14996736
J Hepatol. 2004 Jul;41(1):25-30
pubmed: 15246203
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Aliment Pharmacol Ther. 2007 May 1;25(9):1047-54
pubmed: 17439505
Gastroenterology. 2008 May;134(6):1641-54
pubmed: 18471544
Aliment Pharmacol Ther. 2008 Nov 15;28(10):1188-98
pubmed: 18705692
Hepatology. 2009 Aug;50(2):546-54
pubmed: 19585610
Hepatology. 2009 Oct;50(4):1072-8
pubmed: 19585618
J Viral Hepat. 2010 Dec;17(12):845-50
pubmed: 20070503
World J Gastroenterol. 2010 Feb 28;16(8):966-72
pubmed: 20180235
Gastroenterology. 2010 Sep;139(3):828-35, 835.e1-3
pubmed: 20538000
Drug Alcohol Rev. 2010 Jul;29(4):437-45
pubmed: 20636661
Hepatology. 2012 Feb;55(2):455-64
pubmed: 21993925
J Hepatol. 2014 Jan;60(1):167-74
pubmed: 23973932
Aliment Pharmacol Ther. 2014 Feb;39(3):254-69
pubmed: 24308774
Liver Int. 2015 Apr;35(4):1203-12
pubmed: 24930437
World J Gastroenterol. 2014 Jul 7;20(25):8018-23
pubmed: 25009372
Semin Liver Dis. 2015 May;35(2):146-56
pubmed: 25974900
Hepatology. 2017 Aug;66(2):555-563
pubmed: 28120471
Hepatology. 2017 Jul;66(1):96-107
pubmed: 28170108
Gut Liver. 2017 Mar 15;11(2):173-188
pubmed: 28274107
Gene Expr. 2017 Nov 27;17(4):301-312
pubmed: 28770701
Hepatology. 2018 Mar;67(3):989-1002
pubmed: 29023872
Lancet. 1995 Oct 14;346(8981):987-90
pubmed: 7475591